Home | Welcome to Contract Pharma   
Last Updated Friday, October 24 2014
Print

Financial Report: PAREXEL



Published April 30, 2014
PAREXEL
 
3Q Revenues: $577.9 million (+10%)
 
3Q Earnings: $34.7 million (+18%)
 
YTD Revenues: $1.7 billion (+14%)
 
YTD Earnings: $89.0 million (+35%)
 
Comments: Clinical Research Services (CRS) revenue was $373.2 million in the quarter, up 9%. PAREXEL Consulting (PC) revenue was $51.9 million, up 3%. PAREXEL Informatics (PI) revenue was $67.3 million, up 9%. Backlog at the end of March 2014 was $4.9 billion, an increase of 9%, including new business wins of $781.6 million in the quarter, and cancellations of $208.7 million.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On